Reckitt and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) preterm infants were at an increased risk of developing necrotizing enterocolitis (“NEC”) by consuming the Company’s cow’s milk-based formula, Enfamil; (ii) such risk could impact the Company’s sales of Enfamil and expose the Company to legal claims; and (iii) as a result of the foregoing, the Company’s positive statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.
Shareholders have until August 4, 2025 to request that the court appoint them lead plaintiff.